REGN-COV2 Antibody Treatment Description
REGN-COV2 is a combination of two monoclonal antibodies (REGN10933 and REGN10987) and was designed specifically to block the infectivity of SARS-CoV-2, the coronavirus that causes COVID-19.
Regeneron's core technologies allow for the rapid and efficient generation of these protective anti-viral antibodies outside of the body, derived from either genetically-humanized mice or convalescent humans. The resulting antibodies correspond to the most potent of anti-viral antibodies that could be elicited by a vaccine or through exposure to a pathogen.
These antibodies can be delivered to people via injection, providing "passive immunity" and protection from the disease immediately, though they must be re-administered to remain effective over time. These antibodies can also treat an existing infection, unlike vaccines which can only be used preventatively.
Regeneron's potent, virus-neutralizing antibodies that form REGN-COV2 bind non-competitively to the critical receptor binding domain of the virus's spike protein, which diminishes the ability of mutant viruses to escape treatment and protects against spike variants that have arisen in the human population, as detailed in Science, which was published on August 21, 2020.
The concept that drug cocktails can prevent viral escape has previously been demonstrated for traditional antiviral drugs used to treat HIV and other viruses. Regeneron now reports the fundamental realization that this can also be true for antibody-based therapies as reported in a paper published in Science on August 21, 2020, entitled "Antibody Cocktail to SARS-Cov-2 Spike Protein Prevents Rapid Mutational Escape Seen with Individual Antibodies," which further defines the protective value of the multiple-antibody approach against SARS-CoV-2 specifically.
Regeneron scientists evaluated thousands of fully-human antibodies produced by the company's proprietary VelocImmune® mice, which have been genetically-modified to have a human immune system, as well as antibodies isolated from humans who have recovered from COVID-19.
Regeneron has recently partnered with Roche on August 19, 2020, to increase the global supply of REGN-COV2. If REGN-COV2 proves safe and effective in clinical trials and regulatory approvals are granted, Regeneron will manufacture and distribute it in the U.S., and Roche will develop, manufacture, and distribute it outside the USA.
On October 7, 2020, the company issued a 'Statement on REGN-COV2 Emergency Use Authorization Request: Subsequent to our discussions with regulatory authorities, we have submitted a request to the U.S. Food and Drug Administration for an Emergency Use Authorization (EUA) for our REGN-COV2 investigational antibody combination for COVID-19. Under our agreement with the U.S. government for the initial doses of REGN-COV2, if a EUA is granted the government has committed to making these doses available to the American people at no cost and would be responsible for their distribution. At this time, there are doses available for approximately 50,000 patients, and we expect to have doses available for 300,000 patients in total within the next few months.'
On October 28, 2020, the company announced 'positive, prospective results from an ongoing Phase 2/3 seamless trial in the COVID-19 outpatient setting showing its investigational antibody cocktail, REGN-COV2, met the primary and key secondary endpoints.
In the overall patient population (n=799), patients were prospectively characterized prior to treatment by serology tests to see if they had already generated antiviral antibodies on their own and were thus classified as seronegative (no measurable antiviral antibodies) or seropositive (measurable antiviral antibodies).
Approximately 38% of patients were seropositive, 51% were seronegative and 11% were categorized as "other" due to unclear or unknown serology status. Approximately 50% of patients were Hispanic, 9% were African American and 60.5% had one or more underlying risk factors for severe COVID-19, including obesity (37%). On average, patients were 42.2 years of age. In total, 47% of participants were male and 53% were female.
The Phase 3 portion of this trial continues in non-hospitalized patients. REGN-COV2 is also being studied in a Phase 2/3 clinical trial for the treatment of COVID-19 in hospitalized patients, the Phase 3 open-label RECOVERY trial of hospitalized patients in the UK, and a Phase 3 trial for the prevention of COVID-19 in household contacts of infected individuals.'
REGN-COV2's development and manufacturing has been funded in part with federal funds from the Biomedical Advanced Research and Development Authority under OT number: HHSO100201700020C.
Regeneron (REGN) is a leading biotechnology company that invents life-transforming medicines for people with serious diseases.
REGN-COV2 Antibody Treatment Indication
REGN-COV2 is indicated for the treatment of hospitalized patients, and for the prevention of infection in people who have been exposed to COVID-19 patients.
REGN-COV2 Antibody Treatment Dosage
REGN-COV2 is currently in phase 3 clinical trials to determine the correct dosage.
REGN-COV2 Antibody Treatment News
October 30, 2020 - Regeneron announced it received a recommendation from the independent data monitoring committee for the REGN-COV2 antibody cocktail treatment trials for COVID-19 that the current hospitalized patient trial be modified.
October 28, 2020 - Regeneron Pharmaceuticals, Inc. announced positive, prospective results from an ongoing Phase 2/3 seamless trial in the COVID-19 outpatient setting showing its investigational antibody cocktail, REGN-COV2, met the primary and key secondary endpoints. REGN-COV2 significantly reduced viral load and patient medical visits. "We will submit detailed results from this trial for publication in order to share insights with the public health and medical communities," said David Weinreich, M.D., Senior Vice President and Head of Global Clinical Development at Regeneron.
October 8, 2020 - Study: REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques and hamsters.
October 7, 2020 - The Company issued a 'Statement on REGN-COV2 Emergency Use Authorization Request.'
October 2, 2020 - Regeneron Pharmaceuticals, Inc. confirmed that the company provided a single 8-gram dose of REGNCOV2, a cocktail of two monoclonal antibodies, for use by the US President Trump. REGN-COV2 is an investigational COVID-19 therapy, which was provided in response to an Individual Patient Investigational New Drug application, commonly known as ‘compassionate use’ request, from the President’s physicians.
September 29, 2020 - Regeneron Pharmaceuticals, Inc. announced the first data from a descriptive analysis of a seamless Phase 1/2/3 trial of its investigational antibody cocktail REGN-COV2 showing it reduced viral load and the time to alleviate symptoms in non-hospitalized patients with COVID-19.
September 14, 2020 - Regeneron Pharmaceuticals, Inc. and the University of Oxford today announced that RECOVERY (Randomised Evaluation of COVid-19 thERapY), one of the world's largest randomized clinical trials of potential COVID-19 treatments, will evaluate Regeneron's investigational anti-viral antibody cocktail, REGN-COV2. The Phase 3 open-label trial in patients hospitalized with COVID-19 will compare the effects of adding REGN-COV2 to the usual standard-of-care versus standard-of-care on its own.
August 19, 2020 - Regeneron Pharmaceuticals, Inc. and Roche announced today that they are joining forces to develop, manufacture and distribute REGN-COV2, Regeneron's investigational anti-viral antibody cocktail, to people around the globe. This collaboration is expected to increase the supply of REGN-COV2 to at least three and a half times the current capacity, with the potential for even further expansion.
August 3, 2020 - Non-peer-reviewed study: REGN-COV2 antibody cocktail prevents and treats SARS-CoV-2 infection in rhesus macaques and hamsters.
July 6, 2020 - Regeneron Pharmaceuticals, Inc. announced the initiation of a Phase 3 trial to evaluate REGN-COV2's ability to prevent infection among uninfected people who have had close exposure to a COVID-19 patient (such as the patient's housemate), and is being run jointly with the National Institute of Allergy and Infectious Diseases. REGN-COV2 has also moved into the Phase 2/3 portion of two adaptive Phase 1/2/3 trials testing the cocktail's ability to treat hospitalized and non-hospitalized patients with COVID-19.
June 11, 2020 - Regeneron announced the initiation of the first clinical trial of REGN-COV2, its investigational dual antibody cocktail for the prevention and treatment of COVID-19. The REGN-COV2 clinical program will consist of 4 separate study populations: hospitalized COVID-19 patients, non-hospitalized symptomatic COVID-19 patients, uninfected people in groups that are at high risk of exposure (such as healthcare workers or first responders), and uninfected people with close exposure to a COVID-19 patient (such as the patient's housemate). The placebo-controlled trials will be conducted at multiple sites.
REGN-COV2 Antibody Cocktail Clinical Trials
Clinical Trial NCT04381936: Phase 2/3 Randomised Evaluation of COVID-19 Therapy (RECOVERY) with 15,000 participants - Last Update Posted: September 29, 2020.
- Main randomization (part A): Eligible patients will be randomly allocated between the available treatment arms.
- Main randomization (part B): Simultaneously, eligible patients will be randomly allocated between convalescent plasma, synthetic neutralizing antibodies, or no additional treatment.
- Subsequent randomization: Participants with progressive COVID-19 (as evidenced by hypoxia and an inflammatory state) may undergo optional second randomization.
Clinical Trial NCT04519437: Phase 1 Study Assessing the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Repeated Subcutaneous Doses of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies (REGN10933+REGN10987) in Adult Volunteers as Related to COVID-19
Clinical Trial NCT04425629: Phase 1/2 Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Adult Patients With COVID-19